Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. [electronic resource]
Producer: 20080922Description: 4268-75 p. digitalISSN:- 1527-7755
- Antineoplastic Agents -- therapeutic use
- Canada
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Erlotinib Hydrochloride
- Female
- Genes, erbB-1 -- genetics
- Genotype
- Humans
- In Situ Hybridization, Fluorescence
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Mutation
- Predictive Value of Tests
- Proto-Oncogene Proteins -- genetics
- Proto-Oncogene Proteins p21(ras)
- Quinazolines -- therapeutic use
- Survival Analysis
- ras Proteins -- genetics
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.